The FDA put a slight dent in forecasts for obesity drugs, with a negative view (and decisions) in 2010 that it now seems to be backing away from.
Having forecasted the obesity market earlier this year and having taken a position that the FDA might well revisit its negative decisions on Contrave, Lorcaserin and Qnexa (especially if additional trial data is submitted to address specific concerns), we still hold that there will be substantial upside in obesity drugs (and devices) over the coming decade.
The FDA put a slight dent in forecasts for obesity drugs, with a negative view (and decisions) in 2010 that it now seems to be backing away from.
Having forecasted the obesity market earlier this year and having taken a position that the FDA might well revisit its negative decisions on Contrave, Lorcaserin and Qnexa (especially if additional trial data is submitted to address specific concerns), we still hold that there will be substantial upside in obesity drugs (and devices) over the coming decade.
This is especially true for Europe which, at least in principle, is unaffected by FDA decisions. Below is our forecast of the obesity products market, by specific drug and device types, for Europe through 2019 (sales in $millions).
Source: MedMarket Diligence, LLC; Report S835.
